| Dr Linda Ann Glaser, MD, PHD | |
|
2001 Santa Monica Blvd, Suite 390w, Santa Monica, CA 90404-2102 | |
| (310) 828-2878 | |
| (310) 828-4957 |
| Full Name | Dr Linda Ann Glaser |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Endocrinology, Diabetes & Metabolism |
| Location | 2001 Santa Monica Blvd, Santa Monica, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518900976 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | G71789 (California) | Primary |
| Entity Name | Signify Health Medical Associates Of California Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124685169 PECOS PAC ID: 8325370570 Enrollment ID: O20191022000320 |
News Archive
Researchers from the Cancer Science Institute of Singapore at the National University of Singapore have uncovered a genetic variant in a gene called MET that is responsible for more aggressive growth of head and neck, and lung cancers.
The Special Committee of Independent Directors of Patheon Inc. (TSX:PTI) and Lonza Group AG (SIX:LONN) announced today that Lonza, one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries, has submitted a non-binding proposal to acquire all of the outstanding Restricted Voting Shares of Patheon at a price of US$3.55 per Restricted Voting Share.
SCRA, on behalf of its SC Launch program, today announced that Portfolio Company Immunologix has been acquired by Virginia-based synthetic biology company Intrexon Corporation. The Charleston-based Immunologix team is now part of Intrexon's Protein Production Division.
Ligand Pharmaceuticals Incorporated today announced that it earned a $6.5 million payment from Roche as a result of Roche progressing RG7348 into a Phase I clinical trial for the treatment of hepatitis C viral (HCV) infection. The milestone payment arises from a 2008 collaboration and license agreement between Roche and Metabasis Therapeutics, Inc.
Antigenics Inc. announced that the company received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market LLC (the "Staff") on December 30, 2009 indicating that the company is not in compliance with Nasdaq Marketplace Rule 5550(a)(2) (the "Bid Price Requirement") because the bid price for the company's common stock has closed below the minimum $1.00 per share requirement for 30 consecutive business days.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Linda Ann Glaser, MD, PHD 2001 Santa Monica Blvd, Suite 390w, Santa Monica, CA 90404-2102 Ph: (310) 828-2878 | Dr Linda Ann Glaser, MD, PHD 2001 Santa Monica Blvd, Suite 390w, Santa Monica, CA 90404-2102 Ph: (310) 828-2878 |
News Archive
Researchers from the Cancer Science Institute of Singapore at the National University of Singapore have uncovered a genetic variant in a gene called MET that is responsible for more aggressive growth of head and neck, and lung cancers.
The Special Committee of Independent Directors of Patheon Inc. (TSX:PTI) and Lonza Group AG (SIX:LONN) announced today that Lonza, one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries, has submitted a non-binding proposal to acquire all of the outstanding Restricted Voting Shares of Patheon at a price of US$3.55 per Restricted Voting Share.
SCRA, on behalf of its SC Launch program, today announced that Portfolio Company Immunologix has been acquired by Virginia-based synthetic biology company Intrexon Corporation. The Charleston-based Immunologix team is now part of Intrexon's Protein Production Division.
Ligand Pharmaceuticals Incorporated today announced that it earned a $6.5 million payment from Roche as a result of Roche progressing RG7348 into a Phase I clinical trial for the treatment of hepatitis C viral (HCV) infection. The milestone payment arises from a 2008 collaboration and license agreement between Roche and Metabasis Therapeutics, Inc.
Antigenics Inc. announced that the company received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market LLC (the "Staff") on December 30, 2009 indicating that the company is not in compliance with Nasdaq Marketplace Rule 5550(a)(2) (the "Bid Price Requirement") because the bid price for the company's common stock has closed below the minimum $1.00 per share requirement for 30 consecutive business days.
› Verified 6 days ago
Irawan Susanto, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1223 16th St, Suite 3400, Santa Monica, CA 90404 Phone: 310-449-0939 Fax: 424-259-7790 | |
Louis Ravitz, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 2336 Santa Monica Blvd, Suite 207, Santa Monica, CA 90404 Phone: 310-828-9311 Fax: 310-453-8533 | |
Janet Winikoff, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 2001 Santa Monica Blvd Ste 860, Santa Monica, CA 90404 Phone: 310-828-3209 Fax: 310-828-5165 | |
Dr. Sean Dooley, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2121 Santa Monica Blvd, Santa Monica, CA 90404 Phone: 323-829-8745 | |
Lorraine Anderson, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1245 16th St Ste 303, Santa Monica, CA 90404 Phone: 310-481-4646 Fax: 310-899-7599 | |
Dr. Colleen Lucy Channick, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1223 16th St Ste 3400, Santa Monica, CA 90404 Phone: 310-449-0939 | |
Carol Yukiko Nishikubo, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2001 Santa Monica Blvd Ste 560w, Santa Monica, CA 90404 Phone: 310-453-5654 Fax: 310-453-6885 |